Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients (CUAEPO)

This study has been completed.
Information provided by (Responsible Party):
Mahidol University Identifier:
First received: January 11, 2010
Last updated: September 28, 2015
Last verified: September 2015

To study the cost utility analysis of Erythropoietin (EPO) for maintaining the different hemoglobin (Hb) target levels in anemic hemodialysis patient in routine clinical practice.

Condition Intervention
Chronic Renal Failure
Drug: erythropoietin

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cost-Utility Analysis of Erythropoietin for Anemia Treatmentin Thai End-Stage Renal Disease Patients With Hemodialysis

Resource links provided by NLM:

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • The utility scores of hemodialysis (HD) patients who use EPO to maintain the Hb target level. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Cost of HD patients who use EPO to maintain the Hb target level. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The incremental cost-effectiveness ratio (calculated as the ratio between the incremental differences in costs and QALYs associated with 2 alternative treatments) of EPO at the different Hb target levels in HD patients in routine clinical practice. [ Time Frame: lifetime horizon (Economic evaluation term) ] [ Designated as safety issue: Yes ]

Enrollment: 152
Study Start Date: November 2009
Study Completion Date: September 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
erythropoietin Drug: erythropoietin

Detailed Description:

In Thailand, the studies that were conducted to find the most useful target Hb have not included the cost effectiveness and/or cost utility analyses. The level at which quality of life is maximized and risk is minimized would be the optimal target. Dialysis patients carry higher risk of death than general population. Anemia is the common complication found in dialysis patients that could lead to mortality. Risk of anemia is occurred in HD patients more than CAPD patients because blood loss is less marked and residual renal function maybe better preserved in patients who receive peritoneal dialysis.Although EPO has been included in the National List of Essential Drugs (NLED) for the treatment of anemia caused by end stage renal disease for maintaining the target hemoglobin but the cost of EPO is so expensive. Cost utility analysis is economic technique for assessing the efficiency of healthcare intervention measuring combined outcomes as the effectiveness, i.e., survival and quality of life in combination as quality adjusted life years (QALYs).This study is a benefit measure at the care giving level by using as a part of planning patient management program and at the policy level for decision making.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

HD patients use EPO at least 6 months with titration of EPO therapy is permitted


Inclusion Criteria:

  • Patients use EPO at least 6 months with titration of EPO therapy is permitted

Exclusion Criteria:

  • Patients under 18 years old.
  • Patients who have blood transfusion for anemic treatment within 6 months before EPO treatment and before the study starts
  • Patients who change the modality of dialysis
  • Patients who switch to other anemia treatment method between the study
  • Patients who cannot answer the questionnaire and are not willing to participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01049711

Siriraj Hospital
Bangkok, Thailand
Sponsors and Collaborators
Mahidol University
Principal Investigator: Tanita Thaweethamcharoen, Ph.D Faculty of Medicine, Mahidol University
  More Information

Additional Information:
No publications provided

Responsible Party: Mahidol University Identifier: NCT01049711     History of Changes
Other Study ID Numbers: CUAEPO
Study First Received: January 11, 2010
Last Updated: September 28, 2015
Health Authority: Thailand: Ethical Committee

Keywords provided by Mahidol University:
cost utility
incremental cost-effectiveness ratio
Quality adjusted life year
quality of life

Additional relevant MeSH terms:
Kidney Failure, Chronic
Kidney Diseases
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Epoetin alfa
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 02, 2015